Last reviewed · How we verify
HIV Vaccine 732462
HIV Vaccine 732462 is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | HIV Vaccine 732462 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety of the HIV Vaccine 732462 in HIV Infected Subjects Aged 18 to 55 Years Old (PHASE1)
- Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons (PHASE2)
- Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HIV Vaccine 732462 CI brief — competitive landscape report
- HIV Vaccine 732462 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about HIV Vaccine 732462
What is HIV Vaccine 732462?
HIV Vaccine 732462 is a Biologic drug developed by GlaxoSmithKline.
Who makes HIV Vaccine 732462?
HIV Vaccine 732462 is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is HIV Vaccine 732462 in?
HIV Vaccine 732462 is in Phase 1.
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Compare: HIV Vaccine 732462 vs similar drugs
- Pricing: HIV Vaccine 732462 cost, discount & access